$Scynexis (SCYX.US)$ NEWS SCYNEXIS to Present Preclinical Da...
NEWS
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
SCYNEXIS, Inc. (SCYX) announces the presentation of preclinical efficacy data on SCY-247 at ECCMID 2024, focusing on addressing systemic fungal diseases and invasive fungal infections. SCY-247 shows promise in overcoming drug-resistant infections, particularly against Candida auris.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment